SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-2.29%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$592M
AUM Growth
+$592M
(-4.9%)
Cap. Flow
-$11.6M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
59.76%
Holding
37
New
3
Increased
13
Reduced
9
Closed
3
Top Buys
| 1 |
Eli Lilly
LLY
|
$17M |
| 2 |
United Therapeutics
UTHR
|
$11.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.81M |
| 4 |
Elanco Animal Health
ELAN
|
$6.17M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$5.05M |
Top Sells
| 1 |
Biogen
BIIB
|
$14.6M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
$12.9M |
| 3 |
Abbott
ABT
|
$12.6M |
| 4 |
Viatris
VTRS
|
$9.61M |
| 5 |
CVS Health
CVS
|
$9.58M |
Sector Composition
| 1 | Healthcare | 99.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $70.3M | 11.88% | 1,386,722 +35,000 | +3% | +$1.77M |
|
2
Boston Scientific
BSX
$156B
| $45.1M | 7.62% | 1,108,336 | – | – |
|
|
3
Abbott
ABT
$231B
| $45M | 7.6% | 537,260 -150,000 | -22% | -$12.6M |
|
4
Baxter International
BAX
$12.7B
| $41.3M | 6.98% | 472,305 +10,000 | +2% | +$875K |
|
5
Gilead Sciences
GILD
$140B
| $30.1M | 5.09% | 475,056 +30,000 | +7% | +$1.9M |
|
|
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
| $29.7M | 5.01% | 468,258 -31,096 | -6% | -$1.97M |
|
7
Incyte
INCY
$16.5B
| $25.7M | 4.34% | 345,893 +32,000 | +10% | +$2.38M |
|
8
Revvity
RVTY
$10.5B
| $25.6M | 4.32% | 300,198 | – | – |
|
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $21M | 3.55% | 75,835 +18,200 | +32% | +$5.05M |
|
10
Agilent Technologies
A
$35.7B
| $19.9M | 3.37% | 260,293 -28,772 | -10% | -$2.2M |
|
11
Elevance Health
ELV
$71.8B
| $17.9M | 3.03% | 74,607 +1,500 | +2% | +$360K |
|
|
12
Eli Lilly
LLY
$657B
| $17M | 2.87% | +152,105 | New | +$17M |
|
13
Qiagen
QGEN
$10.1B
| $16M | 2.7% | 484,601 +61,100 | +14% | +$2.01M |
|
|
14
Bio-Rad Laboratories Class A
BIO
$8.06B
| $15.4M | 2.61% | 46,368 -38,658 | -45% | -$12.9M |
|
15
Perrigo
PRGO
$3.27B
| $14.4M | 2.43% | 257,844 -20,000 | -7% | -$1.12M |
|
16
Takeda Pharmaceutical
TAK
$47.3B
| $14M | 2.37% | 816,299 +20,000 | +3% | +$344K |
|
17
Bruker
BRKR
$5.16B
| $13.5M | 2.29% | 308,004 +85,000 | +38% | +$3.73M |
|
|
18
Biogen
BIIB
$19.4B
| $12.2M | 2.06% | 52,426 -62,700 | -54% | -$14.6M |
|
|
19
United Therapeutics
UTHR
$13.8B
| $11.8M | 2% | +148,147 | New | +$11.8M |
|
20
Humana
HUM
$36.5B
| $11.2M | 1.9% | 43,999 -22,901 | -34% | -$5.85M |
|
|
21
Elanco Animal Health
ELAN
$9.12B
| $11.1M | 1.87% | 417,042 +232,000 | +125% | +$6.17M |
|
22
Universal Health Services
UHS
$11.6B
| $9.63M | 1.63% | 64,742 | – | – |
|
23
Tenet Healthcare
THC
$16.3B
| $9.5M | 1.61% | 429,677 +101,015 | +31% | +$2.23M |
|
24
Cardinal Health
CAH
$35.5B
| $9.31M | 1.57% | 197,299 | – | – |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $8.81M | 1.49% | +89,964 | New | +$8.81M |
|